Chronic hepatitis B treatment has a new option in the United States after the FDA approved GSK’s Hibsago (bepirovirsen) on 20 October 2026. It is used together with existing antiviral therapy in certain adults without cirrhosis, and in the supporting trials a minority of patients reached a point where they could stop their existing medicine. This explainer covers what chronic hepatitis B is, how it is treated today, what is new about Hibsago, who can use it, what the trial numbers mean and which questions to take to a liver specialist. It is general information and not medical advice.
Chronic hepatitis B treatment: key takeaways
- Today’s chronic hepatitis B treatment usually suppresses the virus, and the WHO says most people who start treatment must continue it for life.
- Hibsago is added to an existing antiviral for adults without cirrhosis whose virus is suppressed and whose HBsAg is 3,000 IU/mL or less.
- In the trials, 24% of Hibsago patients met the criteria to stop their existing medicine versus none on placebo.
- 19% still had undetectable HBsAg and controlled virus 24 weeks after stopping all treatment, so most patients did not reach this goal.
- The label has a boxed warning for serious liver reactions and low platelet counts.
What chronic hepatitis B is
General background: hepatitis B is a viral infection of the liver. It becomes chronic when the virus is not cleared, and over years it can lead to scarring of the liver, called cirrhosis, and to liver cancer. The WHO hepatitis B fact sheet estimates 240 million people lived with chronic infection in 2024 and about 1.1 million died of related disease that year. It also estimates that 27% of people with the infection knew their status and 4.3% were on antiviral treatment.
How chronic hepatitis B treatment works today
This section is general background. Standard oral antivirals keep the amount of virus in the blood low, which protects the liver. They rarely clear the virus completely, which is why the WHO notes that most people must continue treatment for life. Doctors also monitor a protein made by the virus, hepatitis B surface antigen or HBsAg. Losing HBsAg from the blood, with virus undetectable, is called functional cure and is the goal of many new approaches.
What Hibsago adds to chronic hepatitis B treatment
According to the FDA announcement, Hibsago is the first FDA-approved antisense oligonucleotide for chronic hepatitis B. It targets the viral genetic instructions used to make viral copies and proteins, lowering virus and HBsAg in the body. It is injected under the skin for up to 24 weeks alongside the patient’s existing hepatitis B medicine, and that medicine continues for at least 24 weeks after the last injection. The FDA gave the application Fast Track, Breakthrough Therapy and Priority Review designations.
Who can use this chronic hepatitis B treatment
The approval covers certain adults without cirrhosis who have taken hepatitis B antiviral therapy for at least six months, whose virus is suppressed, and whose HBsAg is 3,000 IU/mL or less as measured by an FDA-authorized test. The agency authorized the Roche Elecsys HBsAg II quant II RxDx assay for selecting and monitoring patients. People with cirrhosis or higher HBsAg are outside the label, and we found no information on how they would be treated.
What the trials found on chronic hepatitis B treatment
The FDA says two trials compared Hibsago with placebo: 24% of Hibsago patients met the criteria to stop their existing medicine versus none on placebo, and 19% had controlled virus with undetectable HBsAg 24 weeks after stopping all treatment. The FDA does not name the trials. They appear to be the Phase III B-Well 1 and 2 studies, an inference of ours. The GSK release on the B-Well trials reports pooled functional cure of 19% (233 of 1,220) versus 0% (0 of 614), and 26% in patients with HBsAg of 1,000 IU/mL or less. These are company figures.
How to read the numbers
This section is general explanation. A rate of 19% means roughly one in five treated patients met the functional cure definition, which also means about four in five did not, by our subtraction. The placebo group had no such cases, which shows the effect is due to the drug and not chance. What the trials cannot yet tell us is how long virus control lasts beyond the follow-up period, or how the numbers would look in a broader group of patients than those studied.
Safety in chronic hepatitis B treatment with Hibsago
The boxed warning covers serious liver reactions and low platelet counts, which can raise the risk of potentially life-threatening bleeding. Other warnings include worsening kidney function, serious inflammatory reactions such as vasculitis, and serious risks if the injection is not given correctly. The most common adverse reactions were injection site reactions, fever, fatigue and headache. Regular blood tests before and during treatment are part of the plan.
Questions to ask a liver specialist about chronic hepatitis B treatment
These suggestions are ours. Am I eligible given my HBsAg level and cirrhosis status? What do my liver tests and platelet counts look like now, and how often would they be checked? What are the chances I could stop my current medicine, and what happens if I cannot? What are the costs and insurance arrangements? Who would give the injections, and what symptoms should prompt an urgent call?
What is not disclosed
- Price and launch date.
- Trial names and enrolment in the FDA announcement.
- Long-term durability of virus control after stopping.
Risks and caveats on chronic hepatitis B treatment news
- Most patients in the trials did not stop treatment or reach functional cure.
- Never stop hepatitis B medicine without medical supervision.
- Trial results are from the FDA and GSK.
- This is general information, not medical advice.
In our assessment, chronic hepatitis B treatment now includes an option aimed at reducing HBsAg and enabling some patients to come off medicine, but it adds monitoring needs and applies to a defined minority of patients. See also GSK Gains Regulatory Momentum for Hepatitis B Treatment as Jemperli Wins FDA Priority Review. More in our pharmaceutical coverage.
What to watch next on chronic hepatitis B treatment
- Price, coverage and launch.
- Longer follow-up of patients who stopped treatment.
- Approvals in other countries.
Frequently asked questions
Can I stop my hepatitis B medicine because of this approval?
Not on your own. Stopping is considered only under medical supervision for patients who meet specific health and laboratory criteria after Hibsago.
What is HBsAg?
It is a surface protein of the hepatitis B virus measured in the blood; the eligibility threshold is 3,000 IU/mL or less.
Is Hibsago available now?
The FDA announced the approval on 20 October 2026; launch timing and price had not been disclosed in the sources we reviewed.
How we reported this: we relied on the FDA announcement, GSK’s trial release and the WHO fact sheet. General background and our suggestions are labelled. Last updated: 21 October 2026. This article is news reporting and education and not medical advice.
